Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 4, Issue 16
August 25 2020
Issue Cover

Table of Contents

BLOOD ADVANCES TALK

The management of venous thromboembolism in hospitalized patients with COVID-19
Clinical Trials & Observations
Alex C. Spyropoulos
View Articletitled, The management of venous thromboembolism in hospitalized patients with COVID-19
Supplemental data

DRUG ADVANCES

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Clinical Trials & Observations
Naveen Pemmaraju,Marina Konopleva
View Articletitled, Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

STIMULUS REPORT

Platelets mediate serological memory to neutralize viruses in vitro and in vivo
Waltraud C. Schrottmaier,Manuel Salzmann,Sigrun Badrnya,Marion Mussbacher,Julia B. Kral-Pointner,Susanne Morava,Anita Pirabe,Laura Brunnthaler,Koon C. Yaiw,Ulrike M. Heber,David Pereyra,Jan T. Andersen,Andreas Bergthaler,Cecilia Söderberg-Nauclér,Mikael C. I. Karlsson,Alice Assinger,Mattias N. E. Forsell
View Articletitled, Platelets mediate serological memory to neutralize viruses in vitro and in vivo
Supplemental data

REVIEW ARTICLE

Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa
Global Advances
Nmazuo W. Ozuah,Joseph Lubega,Carl E. Allen,Nader Kim El-Mallawany
View Articletitled, Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa

CLINICAL TRIALS AND OBSERVATIONS

Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation
Clinical Trials & Observations
Baolin Tang,Lulu Huang,Huilan Liu,Siqi Cheng,Kaidi Song,Xuhan Zhang,Wen Yao,Lijuan Ning,Xiang Wan,Guangyu Sun,Yun Wu,Jiehui Cheng,Qi Long,Zimin Sun,Xiaoyu Zhu
View Articletitled, Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation
Supplemental data
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
Clinical Trials & Observations
David G. Maloney,Michinori Ogura,Noriko Fukuhara,Jaclyn Davis,Janet Lasher,Miguel Izquierdo,Hiya Banerjee,Kensei Tobinai
View Articletitled, A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Clinical Trials & Observations
Heather J. Symons,Marianna Zahurak,Yilin Cao,Allen Chen,Kenneth Cooke,Christopher Gamper,Orly Klein,Nicolas Llosa,Elias T. Zambidis,Richard Ambinder,Javier Bolaños-Meade,Ivan Borrello,Robert Brodsky,Amy DeZern,Ivana Gojo,Margaret Showel,Lode Swinnen,B. Douglas Smith,Leo Luznik,Richard J. Jones,Ephraim J. Fuchs
View Articletitled, Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
Supplemental data
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Clinical Trials & Observations
Jorge J. Castillo,Kirsten Meid,Catherine A. Flynn,Jiaji Chen,Maria G. Demos,Maria L. Guerrera,Amanda Kofides,Xia Liu,Manit Munshi,Nicholas Tsakmaklis,Christopher J. Patterson,Guang Yang,Zachary Hunter,Steven P. Treon
View Articletitled, Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

HEALTH SERVICES AND OUTCOMES

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Julie Kanter,Wally R. Smith,Payal C. Desai,Marsha Treadwell,Biree Andemariam,Jane Little,Diane Nugent,Susan Claster,Deepa G. Manwani,Judith Baker,John J. Strouse,Ifeyinwa Osunkwo,Rosalyn W. Stewart,Allison King,Lisa M. Shook,John D. Roberts,Sophie Lanzkron
View Articletitled, Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Guideline-based indicators for adult patients with myelodysplastic syndromes
Kristina Stojkov,Tobias Silzle,Georg Stussi,David Schwappach,Juerg Bernhard,David Bowen,Jaroslav Čermák,Avinash G. Dinmohamed,Corien Eeltink,Sabrina Eggmann,Pierre Fenaux,Ulrich Germing,Manuel Haschke,Eva Hellstrom-Lindberg,Monika Heger,Arjan A. van de Loosdrecht,Jakob Passweg,Michael Pfeilstöcker,Uwe Platzbecker,Luca Malcovati,António Medina de Almeida,Moshe Mittelman,Christine Morgenthaler,David P. Steensma,Valeria Santini,Reinhard Stauder,Argiris Symeonidis,Sämi Schär,Charlotte Maddox,Theo de Witte,Julia Bohlius,Nicolas Bonadies,on behalf of the Swiss MDS Study Group and the Swiss Group of Clinical Cancer Research (SAKK)
View Articletitled, Guideline-based indicators for adult patients with myelodysplastic syndromes
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation
Maria A. Clavijo-Salomon,Rosalba Salcedo,Soumen Roy,Rodrigo X. das Neves,Amiran Dzutsev,Helioswilton Sales-Campos,Karen Steponavicius-Cruz Borbely,Lucia Silla,Jordan S. Orange,Emily M. Mace,José A. M. Barbuto,Giorgio Trinchieri
View Articletitled, Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation
Supplemental data

LYMPHOID NEOPLASIA

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Clinical Trials & Observations
Paolo Strati,Loretta J. Nastoupil,Jason Westin,Luis E. Fayad,Sairah Ahmed,Nathan H. Fowler,Fredrick B. Hagemeister,Hun J. Lee,Swaminathan P. Iyer,Ranjit Nair,Simrit Parmar,Maria A. Rodriguez,Felipe Samaniego,Raphael E. Steiner,Michael Wang,Chelsea C. Pinnix,Sherry Adkins,Catherine M. Claussen,Charles S. Martinez,Misha C. Hawkins,Nicole A. Johnson,Prachee Singh,Haleigh E. Mistry,Sandra Horowitz,Shirley George,Lei Feng,Partow Kebriaei,Elizabeth J. Shpall,Sattva S. Neelapu,Sudhakar Tummala,T. Linda Chi
View Articletitled, Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E. Roeker,Peter Dreger,Jennifer R. Brown,Oscar B. Lahoud,Toby A. Eyre,Danielle M. Brander,Alan Skarbnik,Catherine C. Coombs,Haesook T. Kim,Matthew Davids,Steven T. Manchini,Gemlyn George,Nirav Shah,Timothy J. Voorhees,Kim H. Orchard,Harriet S. Walter,Arvind K. Arumainathan,Andrea Sitlinger,Jae H. Park,Mark B. Geyer,Andrew D. Zelenetz,Craig S. Sauter,Sergio A. Giralt,Miguel-Angel Perales,Anthony R. Mato
View Articletitled, Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

MYELOID NEOPLASIA

Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Clinical Trials & Observations
Pierre-Yves Dumas,Sarah Bertoli,Emilie Bérard,Thibaut Leguay,Suzanne Tavitian,Jean Galtier,Camille Alric,Audrey Bidet,Eric Delabesse,Jean Baptiste Rieu,Jean-Philippe Vial,François Vergez,Nicolas Lechevalier,Isabelle Luquet,Emilie Klein,Audrey Sarry,Héloïse Rey,Anne-Charlotte de Grande,Fabien Despas,Arnaud Pigneux,Christian Récher
View Articletitled, Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Supplemental data
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation
Juliane Grimm,Madlen Jentzsch,Marius Bill,Karoline Goldmann,Julia Schulz,Dietger Niederwieser,Uwe Platzbecker,Sebastian Schwind
View Articletitled, Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Susanna A. Curtis,Dana Lew,Jonathan Spodick,Jeanne E. Hendrickson,Caterina P. Minniti,John D. Roberts
View Articletitled, Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Supplemental data
Neutrophils from hereditary hemochromatosis patients are protected from iron excess and are primed
Cyril Renassia,Sabine Louis,Sylvain Cuvellier,Nadia Boussetta,Jean-Christophe Deschemin,Didier Borderie,Karine Bailly,Joel Poupon,Pham My-Chan Dang,Jamel El-Benna,Sandra Manceau,François Lefrère,Sophie Vaulont,Carole Peyssonnaux
View Articletitled, Neutrophils from hereditary hemochromatosis patients are protected from iron excess and are primed
Supplemental data

TRANSFUSION MEDICINE

Biological and structural characterization of murine TRALI antibody reveals increased Fc-mediated complement activation
Eveline A. N. Zeeuw van der Laan,Saskia van der Velden,Arthur E. H. Bentlage,Mads D. Larsen,Thijs L. J. van Osch,Juk Yee Mok,Giso Brasser,Dionne M. Geerdes,Carolien A. M. Koeleman,Jan Nouta,John W. Semple,Leendert Porcelijn,Wim J. E. van Esch,Manfred Wuhrer,C. Ellen van der Schoot,Gestur Vidarsson,Rick Kapur
View Articletitled, Biological and structural characterization of murine TRALI antibody reveals increased Fc-mediated complement activation
Supplemental data
Predictive modeling of complex ABO glycan phenotypes by lectin microarrays
Waseem Q. Anani,Heather E. Ashwood,Anna Schmidt,Robert T. Burns,Gregory A. Denomme,Karin M. Hoffmeister
View Articletitled, Predictive modeling of complex ABO glycan phenotypes by lectin microarrays
Supplemental data

TRANSPLANTATION

Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study
Clinical Trials & Observations
Moshe Yeshurun,Uri Rozovski,Oren Pasvolsky,Ofir Wolach,Ron Ram,Odelia Amit,Tsila Zuckerman,Anat Pek,Maly Rubinstein,Michal Sela-Navon,Pia Raanani,Liat Shargian-Alon
View Articletitled, Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study
Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease
Clinical Trials & Observations
Alexander Ngwube,Niketa Shah,Kamar Godder,David Jacobsohn,Monica L. Hulbert,Shalini Shenoy
View Articletitled, Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease
Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
Clinical Trials & Observations
Jacopo Mariotti,Anna Maria Raiola,Andrea Evangelista,Angelo Michele Carella,Massimo Martino,Francesca Patriarca,Antonio Risitano,Stefania Bramanti,Alessandro Busca,Luisa Giaccone,Lucia Brunello,Emanuela Merla,Lucia Savino,Barbara Loteta,Giuseppe Console,Renato Fanin,Alessandra Sperotto,Luana Marano,Serena Marotta,Camilla Frieri,Simona Sica,Patrizia Chiusolo,Samia Harbi,Sabine Furst,Armando Santoro,Andrea Bacigalupo,Didier Blaise,Emanuele Angelucci,Domenico Mavilio,Luca Castagna,Benedetto Bruno
View Articletitled, Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
Supplemental data
Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD
Eleonora Latis,David Michonneau,Claire Leloup,Hugo Varet,Régis Peffault de Latour,CRYOSTEM Consortium,Elisabetta Bianchi,Gérard Socié,Lars Rogge
View Articletitled, Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD
Supplemental data

COMMENTARY

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
Bicky Thapa,Paolo F. Caimi,Kirit M. Ardeshna,Melhem Solh,Carmelo Carlo-Stella,Brad S. Kahl,Mehdi Hamadani
View Articletitled, CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

ERRATUM

Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4(9):1998-2010.
View Articletitled, Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. <em>Blood Adv.</em> 2020;4(9):1998-2010.
All Issues

Advertisement

SGK1 inhibition induces fetal hemoglobin expression and delays polymerization in sickle erythroid cells
Dasatinib-induced spleen contraction leads to transient lymphocytosis
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer
Mitochondrial pyruvate dehydrogenase kinases contribute to platelet function and thrombosis in mice by regulating aerobic glycolysis

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright ©2023 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement